Human Metapneumovirus Diagnostics Global Market Report 2025

The human metapneumovirus diagnostics market size has grown rapidly in recent years. It will grow from $0.49 billion in 2024 to $0.54 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth observed in the historical period can be attributed to an increase in pediatric hospitalization rates due to respiratory infections, heightened awareness of viral respiratory pathogens, the initial adoption of molecular diagnostic tools, the expansion of public health surveillance programs, and greater funding for pediatric respiratory diseases.

The human metapneumovirus diagnostics market size is expected to see rapid growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth anticipated in the forecast period is driven by rising demand for early and accurate respiratory infection diagnostics, growing investments in point-of-care diagnostic solutions, expanding healthcare access in emerging markets, a global focus on pandemic preparedness, and greater integration of multiplex respiratory panels. Key trends in the forecast period include the development of automated and high-throughput diagnostic systems, a shift toward decentralized diagnostic models, the use of artificial intelligence in diagnostic interpretation, the increasing adoption of at-home testing kits, and growing collaboration between public and private diagnostic companies.

The increasing prevalence of respiratory infections is expected to drive growth in the human metapneumovirus diagnostics market. Respiratory infections, caused by viruses, bacteria, or other pathogens, affect the respiratory system, including the sinuses, throat, airways, and lungs. The rising prevalence can be linked to the exposure to harmful pollutants that irritate and weaken the respiratory tract, making it more susceptible to infections. Human metapneumovirus diagnostics help identify hMPV as the cause of respiratory infections, allowing for accurate treatment and better management. For example, in January 2025, the UK Health Security Agency reported that during the 2023-2024 season, respiratory infection rates in England peaked at 8 per 100,000 in weeks 50 and 52 of 2023, and rose further to 10.2 per 100,000 in week 4 of 2024, while acute respiratory infection incidents in closed settings reached 2,051, with most cases reported in care homes and hospitals. This growing prevalence of respiratory infections is fueling the expansion of the human metapneumovirus diagnostics market.

Leading companies in the human metapneumovirus diagnostics market are focusing on developing innovative solutions, such as respiratory polymerase chain reaction (PCR) diagnostic tools, to enhance molecular diagnostic capabilities for detecting a wide range of respiratory pathogens. A respiratory PCR diagnostic solution is a molecular testing method used to detect and identify respiratory pathogens by amplifying their genetic material with high sensitivity and specificity. For example, in March 2023, Jiangsu BioPerfectus Technologies Co., Ltd., a molecular diagnostic company based in China, launched its respiratory pathogen multiplex real-time PCR diagnostic kit. This solution is designed to simultaneously detect multiple respiratory pathogens with high accuracy and a rapid turnaround time, improving diagnostic efficiency in clinical and point-of-care settings. Its broad coverage and precise performance significantly aid timely clinical decision-making, particularly for managing respiratory infections with overlapping symptoms.

In February 2024, AstraZeneca plc, a pharmaceutical company based in the UK, acquired Icosavax Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to enhance its late-stage pipeline and expand its expertise in vaccines for respiratory conditions with high burdens, specifically advancing Icosavax’s lead investigational combination vaccine candidate, IVX-A12, which targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Icosavax Inc., a biotechnology company based in the US, focuses on developing vaccines, especially combination vaccines targeting respiratory viruses such as RSV and hMPV.

Major players in the human metapneumovirus diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Quest Diagnostics, Hologic Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, Qiagen NV, Diasorin, Luminex Corporation, bioMérieux, Seegene Inc., Cepheid, R-Biopharm AG, Certest Biotec, ZeptoMetrix, Xi'an Tianlong Science and Technology Co. Ltd, The Native Antigen Company, Hangzhou Testsea Biotechnology Co. Ltd., and Attogene.

North America was the largest region in the human metapneumovirus diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human metapneumovirus diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human metapneumovirus diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Human metapneumovirus (hMPV) diagnostics involve the methods and criteria used to detect and confirm infection with human metapneumovirus, a respiratory pathogen that can cause illnesses ranging from mild cold-like symptoms to severe respiratory infections, particularly in children, the elderly, and immunocompromised individuals.

The primary product types in human metapneumovirus diagnostics are reagents and kits, as well as instruments. Reagents and kits are essential laboratory products that contain chemical substances and tools for performing specific diagnostic tests or experiments. The diagnostic test types include molecular diagnostics, immunodiagnostics, culture-based methods, and others, utilizing technologies such as PCR-based diagnostics, next-generation sequencing (NGS), immunofluorescence assays, lateral flow assays, microarray technology, and others. These tests are used in various settings, including hospitals and clinics, diagnostic and reference laboratories, academic and research institutions, among others.

The human metapneumovirus diagnostics market research report is one of a series of new reports that provides human metapneumovirus diagnostics market statistics, including human metapneumovirus diagnostics industry global market size, regional shares, competitors with a human metapneumovirus diagnostics market share, detailed human metapneumovirus diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the human metapneumovirus diagnostics industry. This human metapneumovirus diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human metapneumovirus diagnostics market consists of revenues earned by entities by providing services such as diagnostic testing services, clinical laboratory services, point-of-care testing services, home sample collection services, public health surveillance services, and contract research and testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus diagnostics market also includes sales of sample collection devices, diagnostic data management tools, test validation kits, and safety and waste disposal systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.